Sun Pharma/Taro $200M Generic Drug Settlement

At a glance

Status

Approved, awaiting payment

Defendant

Sun Pharmaceutical Industries, Inc.; Taro Pharmaceuticals U.S.A., Inc.

Settlement fund

$200,000,000

Claim deadline

November 9, 2026

No-proof cash option

Yes — pro rata cash (end-payer consumer/third-party-payor class)

Estimated payout

pro rata cash (end-payer consumer/third-party-payor class)

Administrator

A.B. Data, Ltd. (inferred from the site's privacy-policy hosting domain; not explicitly labeled 'Administrator' on the pages read)

Official site

genericdrugsendpayersettlement.com/sun-taro-classes-homepage

Court

U.S. District Court, Eastern District of Pennsylvania

Case number

In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL 2724), No. 16-MD-2724

Last verified September 9, 2026

Key dates

Milestone	Date	What it means
Claim deadline	November 9, 2026	Last day to file for a payment
Opt-out (exclusion) deadline	None listed	Last day to leave the settlement and keep the right to sue
Objection deadline	None listed	Last day to object to the terms
Final approval hearing	None listed	When the judge decides whether to approve the settlement
Expected payout	Not yet scheduled	Payments are not sent until after final approval and any appeals

Where to file

Sun Pharmaceutical / Taro Generic-Drug Price-Fixing End-Payer Settlement is administered by A.B. Data, Ltd. (inferred from the site's privacy-policy hosting domain; not explicitly labeled 'Administrator' on the pages read). The only place to file is the official settlement website:

Verify on the official site

genericdrugsendpayersettlement.com/sun-taro-classes-homepage

Filing is free. No legitimate settlement charges a fee to file a claim.

You cannot file on RecordingLaw.com. We are an independent publisher, not the settlement administrator, and we are not affiliated with any court, agency, or defendant.

The Sun Pharmaceutical/Taro Generic-Drug Price-Fixing End-Payer Settlement is an antitrust case, not a data breach. As of July 2026, the court has already granted final approval to the $200 million fund, and the deadline to file a claim is November 9, 2026. "End-payer" is legal shorthand for whoever ultimately bore the cost of a drug, whether that is a consumer paying a copay at the pharmacy counter or a health plan reimbursing the claim, as opposed to a wholesaler further up the supply chain. If you or your health plan paid for certain generic prescription drugs between 2009 and 2019, here is what the case alleges, where the settlement actually stands, and how filing works.

What the lawsuit is about

This case is part of a large multidistrict antitrust litigation known as In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, pending in the U.S. District Court for the Eastern District of Pennsylvania under case number 16-MD-2724. Within that litigation, end-payers, meaning consumers and third-party payors who ultimately bore the cost of certain generic prescription drugs, allege that generic drug manufacturers, including Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc., conspired to fix and inflate prices rather than compete on price as federal and state antitrust law requires.

"End-payer" is the term to understand here. A generic drug moves from manufacturer to wholesaler to pharmacy before it reaches you. A "direct purchaser" case covers the wholesalers and distributors that bought straight from the manufacturer. An "end-payer" case, like this one, covers the people and entities at the very end of that chain: consumers who paid a copay, coinsurance, or the full cash price at the pharmacy counter, and third-party payors, meaning health plans, insurers, unions, and self-funded employer plans, that reimbursed pharmacy claims for the drugs at issue.

Sun Pharmaceutical and Taro agreed to resolve the end-payer claims against them for a combined $200 million, without admitting wrongdoing. This is one of several settlements reached with different defendant groups inside the same broader MDL; other manufacturers named in the litigation are handled through separate settlements or remain in active litigation.

Where this stands right now, and why

As of July 2026, this settlement has already cleared one of the biggest hurdles in a class action: final court approval. The official settlement site confirms the case has received final approval, the $200 million fund, and the Eastern District of Pennsylvania as the presiding court.

What has not happened yet is payment. No expected payout date is stated in the record verified for this page. That is ordinary at this stage; funds in a settlement like this are typically not released to claimants until after final approval and, often, after any appeal period runs, so a gap of many months between "approved" and "checks mailed" is normal, not a sign anything has gone wrong.

The official site also states that the objection and exclusion, or opt-out, deadlines for this settlement have already passed, though it does not list the exact date they fell on. If you wanted to exclude yourself from the class to keep your own right to sue separately, or you wanted to object to the settlement's terms, those windows have closed. What remains open is the claims process itself: the deadline to file a claim for a payment from the fund is November 9, 2026.

Who's actually in the class

The end-payer class covers consumers and third-party payors who purchased, paid for, or reimbursed certain generic prescription drugs in the United States between May 1, 2009 and December 31, 2019. In practice, that means two kinds of claimants: individuals who paid out of pocket, such as a copay, coinsurance, or the full cash price, for a covered generic drug during that window, and third-party payors, such as health insurers, union benefit funds, and self-insured employer health plans, that reimbursed pharmacy claims for those drugs.

The verified record for this page does not list which specific generic drugs are covered. If you are unsure whether a medication you or your health plan paid for during that decade falls within this case, the official settlement site is the place to check, not a search engine or a third-party settlement tracker.

How much you can realistically expect

There is no set or guaranteed payment amount. The $200 million fund is a common pool divided pro rata among everyone who files a valid claim, so what you would actually receive depends on two things this page cannot predict: how many other people and payors file claims, and what the court approves for attorneys' fees, administrative costs, and any incentive awards to the named plaintiffs. Any early estimate can be adjusted up or down once those numbers are known.

Because this is a nationwide class covering roughly a decade of purchases, expect an individual consumer payment to be modest. A third-party payor that processed large claim volumes may end up with a materially different figure than an individual who bought a single prescription, but neither amount is fixed until the claims and distribution process runs its course.

What proof you need to file

The verified record for this page does not specify what documentation, if any, the administrator requires to support a claim. Do not assume you need pharmacy receipts, insurance statements, or an exact purchase history before you start; check the claim form and instructions on the official settlement site directly, since requirements like this can differ for an individual consumer versus a third-party payor filing on behalf of a plan.

How filing works

Filing happens only through the official settlement site for this case, genericdrugsendpayersettlement.com, specifically its Sun and Taro classes page; the link renders separately on this page. The deadline to file a claim is November 9, 2026.

Keep in mind that this end-payer settlement is separate from an $85 million direct-purchaser settlement reached earlier in the same broader litigation, which has its own site and is meant for wholesalers and distributors, not consumers or health plans. If you are an individual or a health plan, the end-payer site is the one that applies to you.

If you're not sure this applies to you, or you're checking back later

This is a civil antitrust case about alleged price-fixing, not a data breach, so no personal data exposure is alleged, and the credit-freeze or identity-monitoring steps that make sense after an actual breach are not relevant to this claim.

For other open, currently verified settlements, including actual data breach cases with their own separate claim windows, see RecordingLaw's data breach and privacy settlement tracker.